Zealand Pharma, the Danish biotech known for its GLP-1-based obesity and diabetes treatments, has struck a partnership with Generate Biomedicines to develop next-generation weight-loss drugs using AI-driven protein design. The deal adds an AI drug discovery dimension to Zealand’s growing obesity drug pipeline, as the company seeks to differentiate itself in an obesity treatment market increasingly crowded by giants including Novo Nordisk and Eli Lilly.
Multispecific proteins: the next frontier
The partnership centers on multispecific protein therapies — drugs engineered to simultaneously act on multiple biological targets, rather than the single-target mechanism that defined earlier generations of GLP-1 obesity drugs like semaglutide. Designing proteins that reliably hit multiple targets with the right balance of effects is an extraordinarily complex engineering challenge, one that Generate Biomedicines has built its AI platform specifically to address, using generative models trained to design novel protein structures with specified functional properties.
Why obesity drug developers are racing toward multi-target drugs
The first wave of GLP-1 obesity drugs demonstrated dramatic weight-loss results but also revealed limitations, including muscle mass loss alongside fat loss and plateauing effectiveness in some patients — problems that have driven an industry-wide push toward multi-target drugs designed to preserve lean muscle mass while maintaining or improving fat-loss efficacy. Eli Lilly’s own pipeline has moved in a similar multi-target direction, reflecting a broader consensus among obesity drug developers that the next generation of treatments will need to go beyond single-target GLP-1 mechanisms to meaningfully improve on current drugs’ side-effect profiles.
Generate’s AI approach
Generate Biomedicines has positioned its generative AI protein design platform as capable of creating entirely novel protein structures optimized for specific therapeutic functions, rather than starting from naturally occurring proteins and modifying them incrementally — an approach the company argues allows it to explore a vastly larger design space than traditional protein engineering methods. The company has pursued partnerships across multiple disease areas beyond obesity, positioning its core AI protein design technology as broadly applicable rather than specific to any single therapeutic category.
Zealand’s competitive position
Zealand Pharma has built its business around a focused obesity and metabolic disease pipeline, a strategy that has made it an attractive partner or acquisition target as larger pharmaceutical companies seek to bolster their own obesity drug portfolios amid surging global demand for weight-loss treatments. The Generate partnership gives Zealand access to AI-driven protein design capability it likely could not have built as quickly in-house, while Generate gains a specialized obesity-focused partner with existing clinical development and regulatory expertise in the category.
The competitive and financial stakes
The global obesity drug market has become one of the most closely watched and valuable categories in all of pharmaceuticals, with Novo Nordisk’s and Eli Lilly’s existing GLP-1 drugs generating tens of billions of dollars in annual revenue — stakes high enough that nearly every major pharmaceutical company has either developed or partnered for its own obesity drug candidates. AI-driven protein design partnerships like Zealand’s with Generate represent one of several parallel strategies companies are pursuing to capture a share of that market with next-generation, differentiated drugs.
What it means next
Any multispecific protein candidates emerging from the Zealand-Generate partnership would still need to clear the full gauntlet of preclinical testing and multi-phase clinical trials before reaching patients, a process that typically takes years even for well-funded, high-priority programs in a hot therapeutic category. The partnership’s near-term significance lies less in any immediate drug candidate than in what it signals about AI protein design’s growing role in one of pharma’s most commercially important and competitive therapeutic areas.
Photo: stevepb / PIXABAY via Pixabay
